avexitide
Peptide
Evidence outlook · lead readout
LUCIDITY (NCT06747468) · Post-Bariatric Hypoglycemia
The completed lead evidence is positive, with design limits that temper confidence; the rationale below says which.
LUCIDITY (NCT06747468): LUCIDITY was a randomized, double-blind, placebo-controlled Phase 3 in post-bariatric hypoglycemia. Its primary endpoint, the rate of clinically significant hypoglycemic events, is a clinical outcome and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate.
Company guidance: regulatory filing expected by the end of 2026 (Amylyx Pharmaceuticals, Inc., 5 Nov 2026). “We plan to submit a New Drug Application, or NDA, for avexitide to the FDA by the end of 2026.” Source ↗
Company guidance: regulatory filing expected by end of 2026 (NCT06747468; Amylyx Pharmaceuticals, Inc., 5 Nov 2026). “Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
LUCIDITY NCT06747468 · Post-Bariatric Hypoglycemia LUCIDITY was a randomized, double-blind, placebo-controlled Phase 3 in post-bariatric hypoglycemia. Its primary endpoint, the rate of clinically significant hypoglycemic events, is a clinical outcome and was met according to the company's topline release. The sources read give no power calculation, so the grade is moderate. Registry: NCT06747468 | 3 | Composite rate of Level 2 and Level 3 hypoglycemic events (During the double-blind treatment period (approximately 16 weeks)); Safety and Tolerability of avexitide (During the double-blind treatment period (approximately 16 weeks)); Incidence of anti-drug antibodies (ADAb) (During the double-blind treatment period (approximately 16 weeks)) 2026-07-08 | Primary endpoint met: 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events vs placebo (Amylyx, 2026-08-18). | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent